AmDen Pharmaceuticals Denmark ApS: Financial statements 2025
CVR: 42045403
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
AmDen Pharmaceuticals Denmark ApS (CVR 42045403) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -7,514 and a net result of DKK -4,907 compared with DKK -7,596 the year before. Equity in the 2025 report amounted to DKK 17,994. The solvency ratio was 58.5%.
- Gross Profit
- DKK -7,514
- Profit/Loss
- DKK -4,907
- Equity
- DKK 17,994
- Total Assets
- DKK 30,745
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -8K | -5K | 18K | 0 |
| 2024 | - | -8K | -8K | 23K | 1 |
| 2023 | - | -5K | -5K | 30K | 1 |
| 2022 | - | -7K | -15K | 35K | 1 |
| 2021 | - | 750K | 584K | 624K | 1 |
Official annual report
How creditworthy is AmDen Pharmaceuticals Denmark ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
AmDen Pharmaceuticals Denmark ApS has published its annual report for 2024. Gross profit came to DKK -7,807, and the net result was DKK -7,596.
About AmDen Pharmaceuticals Denmark ApS
AmDen Pharmaceuticals Denmark ApS is a Danish company of the type Anpartsselskab based in Køge, founded in 2021. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Flemming Dyremose and Mikael Søndergaard Thomsen. The company is owned by Thomsen Pharma ApS and Flandy Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -7,514 and a net result of DKK -4,907 compared with DKK -7,596 the year before. Equity in the 2025 report amounted to DKK 17,994.